dr. o'connor discusses acalabrutinib in mcl
Published 6 years ago • 73 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:46
dr. o'connor on acalabrutinib versus ibrutinib in mcl
-
1:42
dr. o'connor on treatment options following ibrutinib progression in mcl
-
1:45
dr. o'connor on recent fda approvals in mcl
-
1:45
dr. patel discusses promise of acalabrutinib in mcl
-
1:25
dr. o'connor on cd30 expression in dlbcl
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
1:26
what is the prognosis for mantle cell lymphoma?
-
8:57
calquence® (acalabrutinib) perspectives: dr andre goy, md
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
0:58
dr. wang discusses acalabrutinib in mcl
-
0:43
dr. wang discusses next steps with acalabrutinib in mcl
-
1:20
dr. wang discusses single-agent acalabrutinib in mcl
-
0:54
dr. wang on updated data with single-agent acalabrutinib in mcl
-
15:10
ash 2018: dr. o'connor shares insight on mcl and t-cell lymphoma advances
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:21
dr. brown discusses acalabrutinib in cll
-
3:19
fda-approved agents for the treatment of mcl
-
0:50
dr. furman on acalabrutinib monotherapy in cll
-
1:06
dr. goy on promising data with acalabrutinib in mcl
-
1:41
dr. logan discusses acalabrutinib in cll
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl